Jubilant HollisterStier LLC launches New High-Speed Isolator based Line, at its Spokane Manufacturing Facility in the US

Jubilant Pharmova Limited announced today that Jubilant HollisterStier LLC (JHS)-a wholly owned subsidiary and a leading North American pharmaceutical contract manufacturer, specialising in sterile injectables and serving top global innovator pharma companies-successfully launched its New Sterile Fill & Finish line, third at its Spokane Manufacturing Facility in Washington, US. The launch was marked by the successful production of the inaugural batch, initiating revenue generation from the new Line. This milestone denotes a significant advancement in Jubilant HollisterStier's multi-phase expansion strategy and brings an additional 50% capacity at its Spokane manufacturing facility.

The New Line features advanced isolator technology designed to deliver enhanced sterility assurance, throughput and operational precision. Built to meet the highest global regulatory standards, the New Line significantly enhances the Company's ability to support complex injectable programs across a broad range of therapeutic areas. The US$ 132 million investment towards this New Third Line, reflects the Company's long-term commitment to innovation, quality and supply chain resilience.

Together with the commissioning of its upcoming Fourth Line, JHS is on track to double its total sterile injectable manufacturing capacity at its Spokane facility in the US. This strategic investment further reinforces JHS' leadership in domestic US pharmaceutical manufacturing. By expanding its infrastructure and increasing onshore capacity, the Company is contributing to US national health security and helping to reduce reliance on offshore supply chains-delivering a more resilient and agile pharmaceutical manufacturing ecosystem.

Commenting on the development, Chris Preti, CEO - CDMO Sterile Injectables said, "Launching our Third Line is more than a milestone for us-it's a defining moment in Jubilant HollisterStier's journey. This expansion also reflects our deep-rooted commitment, to continued growth, technological excellence and the community at Spokane. With Third Line now operational and Fourth Line on the horizon, we are not just doubling our capacity, we're building a future that will create hundreds of new jobs, strengthen the US pharmaceutical supply chain and reaffirm our role as a trusted partner in delivering life-saving therapies to patients around the world." He further added, "In the wake of new tariffs imposed by the US Government, large innovator pharma companies are looking for high quality, US manufacturing facilities. Therefore, we are witnessing a very strong traction in Requests for Proposals (RFPs) for the New Line. We expect to reach the full utilisation for the New Line in the next 3 years."

Trusted by 5 of the top 20 global pharma companies as partners, JHS has a 92% customer retention rate that reflects high level of customer satisfaction. It also has a proven track-record, with regulatory organisations like the US FDA, EMA, PMDA Japan, Health Canada, ANVISA Brazil and other bodies in over 140 countries worldwide.

Shares of Jubilant Pharmova Limited was last trading in BSE at Rs. 1095.70 as compared to the previous close of Rs. 1086.25. The total number of shares traded during the day was 4636 in over 480 trades.

The stock hit an intraday high of Rs. 1105.65 and intraday low of 1082.05. The net turnover during the day was Rs. 5088189.00.

Source : Equity Bulls

Keywords

JubilantPharmova INE700A01033 Pharmaceuticals JubilantHolliStierLLC